Copper complex and application thereof
By developing copper complexes and using DPQ and amino acids as ligands to build stable and targeted copper complexes, the immunosuppression problem in tumor immunotherapy is solved, and the stability and biosafety of copper death inducers are achieved. It significantly improves the immunogenicity and anti-tumor efficacy of tumor cells, especially for triple-negative breast cancer.
Patent Information
- Application Number
- CN202410933311.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-05
AI Technical Summary
The existing tumor immunotherapy is poor in tumor cells due to the presence of tumor immunosuppressive microenvironment and immunosuppressive cells, which limits the effectiveness of immunotherapy, and the stability and biosafety of copper death inducers limit their application. .
Develop a copper complex, using DPQ as the main ligand and amino acid as the auxiliary ligand, to build a copper complex with stability and targetability, and use π-π stacking and hydrogen bonding to enhance stability, improve water solubility and Intracellular activity, forming copper death inducers independent of copper ion carriers.
This copper complex can effectively induce copper death in tumor cells, improve the immunogenicity of tumor cells, break the immunosuppressive microenvironment, significantly enhance the anti-tumor immune response, and show significant anti-tumor efficacy in the body, especially for triple-negative breast cancer The cells have significant inhibitory effects.
Smart Images

Figure CN118894872A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a copper complex and application thereof. Background Art
[0002] High tumor heterogeneity, complex TME and weak immunogenicity are the main reasons for the poor efficacy of current tumor treatment. Recently emerging immunotherapies have shown unique advantages in reactivating the immune system to identify and fight cancer cells. However, there are currently two obvious reasons that limit the effectiveness of tumor immunotherapy: (1) Most tumor immune phenotypes are immune desert type, i.e. "cold" tumors, with poor tumor immunogenicity and lack of sufficient T cell and co-stimulatory molecule infiltration; (2) The tumor immunosuppressive microenvironment composed of immunosuppressive cells and inhibitory protein molecules is more suitable for tumor growth and inhibits the killing function of effector T cells. Therefore, different treatment strategies need to be adopted to regulate the problems in tumor immunotherapy in order to achieve good tumor immunotherapy effects.
[0003] Immunogenic cell death (ICD) is a rare form of immunostimulatory cell death that can activate the tumor-specific immune system. It is mainly manifested in that cells upregulate the expression of related characteristic protein molecules or release them to the extracellular space after being stimulated by chemotherapy or drugs, such as calreticulin (CRT), high-mobility group protein 1 (HMGB1) and adenosine triphosphate (ATP), thereby increasing the immunogenicity of tumor cells and inhibiting cancer cells. Inducing ICD can improve the immunogenicity of tumor cells and resist the immunosuppressive microenvironment to a certain extent. Currently, effective ICD is induced by apoptosis, that is, immunogenic apoptosis, but apoptosis is easily cleared by macrophages, resulting in inflammatory quenching, which greatly limits the therapeutic benefits obtained by inducing ICD in cancer treatment. Therefore, there is an urgent need to induce a new cell death mode that is highly immunogenic in cancer cells, which can be used as an independent treatment method or as a complementary strategy for immunotherapy.
[0004] Copper death, as a newly discovered mode of cell death, can circumvent the resistance induced by apoptosis in tumor cells. The copper metabolism of normal cells is homeostatically regulated, while the copper metabolism of tumor cells is dysregulated. Metabolically active tumor cells are more susceptible to copper death. Copper deficiency or copper overload can cause metabolic disorders and produce cytotoxicity, so the elimination of copper in tumors and the oversupply of copper can inhibit the growth of cancer, and copper-related cancer treatment also follows these two basic strategies. At present, cancer treatment research based on copper death is mainly divided into two methods. The first category involves the use of copper ion carriers, such as disulfiram and ilisimol, by transporting copper ions into cells and inducing copper death. However, due to changes in copper ion metabolism and the effectiveness of copper ion carriers, it is still challenging to achieve copper death in tumor cells. The second method uses sonosensitizers / photosensitizers combined with copper ion carriers to form nanoparticles. These nanoparticles release copper ions in the tumor area through external stimulation, resulting in cell copper death. However, the stability and biosafety of copper ion carriers and nanoparticles formed by copper ions limit the application of this method. Therefore, it is of great significance to develop a stable copper death inducer that is independent of copper ion carriers. Summary of the invention
[0005] In view of this, the present invention provides a copper complex and its application. As a copper death inducer, the copper complex can circumvent the resistance induced by tumor cell apoptosis, improve the immunogenicity of tumor cells and the ability to resist the immunosuppressive microenvironment to a certain extent, and overcome the shortcomings of current tumor immunotherapy.
[0006] In order to solve the above technical problems, the first aspect of the present invention provides a copper complex, the chemical formula of the copper complex is one of the following structural formulas:
[0007] [Cu(DPQ)(Tyr)(H2O)]PF6·2.5H2O Formula I,
[0008] [Cu(DPQ)(Gly)(NO3)(H2O)]·1.5H2O Formula II,
[0009] [Cu(DPQ)(Ala)(H2O)]·NO3 Formula III
[0010] or [Cu(DPQ)(Cys)] + Formula IV;
[0011] Among them, DPQ is pyrazino[2,3-f][1,10]phenanthroline, Tyr is tyrosine, Gly is glycine, Ala is alanine, Cys is cysteine, PF6 is hexafluorophosphate, and NO3 is nitrate.
[0012] DPQ has unique electronic properties and conjugated structure, and its planar aromatic ring structure is easy to enter and penetrate the cell membrane, and has certain biological activity, but its anti-breast cancer activity is not high, and its water solubility is poor, which is not conducive to the in vivo absorption of drugs. The present invention uses DPQ as the main ligand, and enhances the stability of the complex itself through π-π stacking and hydrogen bonding, and the obtained copper complex has a strong lipophilicity, which is conducive to the entry of drugs into cells. The present invention uses amino acids as auxiliary ligands, and regulates the lipid-water partition coefficient by constructing different molecular skeletons, thereby improving the water solubility of the copper complex and changing the activity of the copper complex entering the cell. In addition, the present invention increases the targeting of the copper complex to tumor cells by virtue of the affinity of tumor cells to amino acids. Compared with the separate ligand DQP and copper ion carrier, the copper complex provided by the present invention produces a synergistic effect.
[0013] In combination with the first aspect, the copper complex I crystal belongs to the orthorhombic system, the space group is P 21 21 21, and the unit cell parameters are α=90°,β=90°,γ=90°,Z=4,unit cell volume The copper complex II crystal belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=85.813(3)°,β=88.092(3)°,γ=71.145(3)°,Z=2,unit cell volume The copper complex III crystal belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=80.096(4)°,β=82.903(4)°,γ=85.189(4)°,Z=2,unit cell volume The copper complex IV crystal belongs to the orthorhombic system, the space group is P bca, and the unit cell parameters are α=90,β=90°,γ=90°,Z=8,unit cell volume
[0014] The second aspect of the present invention provides a method for preparing the above-mentioned copper complex, comprising the steps of: dissolving equimolar amounts of amino acids and alkali in water, adding an alcohol solution containing equimolar amounts of metal copper salt and ligand under stirring at room temperature, heating under reflux and stirring for 3 to 5 hours, continuing to heat under reflux for 2 hours or stirring at room temperature for 1 hour, filtering, and volatilizing the filtrate at room temperature. After 3 to 5 weeks, blue crystals of the copper complex are obtained.
[0015] In combination with the second aspect, after heating under reflux and stirring for 3 to 5 hours, an equimolar amount of hexafluorophosphate is added, and then heating under reflux is continued for 2 hours.
[0016] In combination with the second aspect, the hexafluorophosphate includes at least one of potassium hexafluorophosphate, lithium hexafluorophosphate, sodium hexafluorophosphate and ammonium hexafluorophosphate.
[0017] In combination with the second aspect, the metal copper salt includes at least one of copper chloride, copper bromide, copper carbonate, copper nitrate and copper perchlorate.
[0018] The third aspect of the present invention provides a pharmaceutical composition of a copper complex, comprising the above copper complex and an excipient.
[0019] The fourth aspect of the present invention provides a use of the copper complex in preparing a copper death inducing agent or in preparing an anti-tumor stemness drug.
[0020] The fifth aspect of the present invention provides a use of the above copper complex in the preparation of an anti-triple-negative breast cancer drug.
[0021] In combination with the fifth aspect, the anti-triple-negative breast cancer cells are anti-triple-negative breast cancer cells CAL-51, MDA-MB-231 and / or MDA-MB-468.
[0022] Due to its special biological behavior and clinical pathological characteristics, triple-negative breast cancer has a high degree of malignancy and a poor prognosis than other types of breast cancer. The present invention determines the crystal structure of the above copper complex by elemental analysis, infrared spectroscopy and single crystal X-ray diffraction experiments, and evaluates its in vitro antitumor activity by MTT method. The results show that the above copper complex has significant anticancer activity against triple-negative breast cancer cells CAL-51, MDA-MB-231 and MDA-MB-468. The present invention further confirms that the above copper complex has significant antitumor efficacy through in vivo animal experiments.
[0023] The present invention mainly uses triple-negative breast cancer cells as the research object. After incubating with the copper complex for a certain period of time, MTT experiments, flow cytometry experiments, tumor stem cell microsphere formation experiments, cell scratch experiments and protein immunoblotting experiments are used to confirm that the above-mentioned copper complex can induce tumor cell copper death, inhibit tumor stemness, enhance the ICD effect, and then activate the anti-tumor immune response, break the immunosuppressive microenvironment, and may make a breakthrough in improving the effect of existing immunotherapy.
[0024] The present invention designs and synthesizes four novel copper complexes, evaluates their antitumor activity in vitro, and finds that they have significant antitumor activity against selected triple-negative breast cancer cells (CAL-51, MDA-MB-468, and MDA-MB-231). 50The value range is 0.13-0.42 μM. Cell scratch test, tumor cell microsphere formation test, flow cytometry test and protein immunoblotting test show that the copper complex can induce tumor cell copper death and inhibit tumor stemness, and in vivo experiments confirm that the copper complex provided by the present invention has significant in vivo therapeutic effect. In addition, the copper complex provided by the present invention can also be used as a potential anti-tumor stemness drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 is the unit structure diagram of copper complex Ⅰ;
[0026] Figure 2 is the infrared spectrum of copper complex Ⅰ;
[0027] Figure 3 This is the unit structure diagram of copper complex II;
[0028] Figure 4 is the infrared spectrum of copper complex II;
[0029] Figure 5 It is the unit structure diagram of copper complex III;
[0030] Figure 6 is the infrared spectrum of copper complex III;
[0031] Figure 7 is the unit structure diagram of copper complex IV;
[0032] Figure 8 is the infrared spectrum of copper complex IV;
[0033] Fig. 9 , (a) is the effect of the control group, cisplatin group, copper complex I and copper complex III on the migration ability of MDA-MB-468 cells, (b) is the relative migration rate bar graph of the control group, cisplatin group, copper complex I and copper complex III;
[0034] Fig.10 Microscopic photos of MDA-MB-468 cell mammospheres in the control group, cisplatin group, and different concentrations of copper complex I and copper complex III at different time points;
[0035] Fig.11 , (a) is the effect of the control group, copper complex I and copper complex III at different concentrations on the tumor stemness marker CD44+CD24- after incubation with MDA-MB-468 cells for 48 hours, (b) is a bar graph of the inhibition of cell stemness by the control group, copper complex I and copper complex III;
[0036] Fig.12MDA-MB-468 cells were incubated with different concentrations of copper complexes Ⅰ and Ⅲ for 48 hours, and the expression levels of tumor stemness-related proteins Nanog, SOX2, Vimentin and E-cadherin were detected by western blotting;
[0037] Fig.13 MDA-MB-468 cells were incubated with different concentrations of copper complexes Ⅰ and Ⅲ for 48 hours, and the expression levels of copper death-related proteins DLAT, LIAS and FDX1 in tumor cells were detected by western blotting. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0039] DPQ (full name in Chinese: pyrazino[2,3-f][1,10]phenanthroline) has unique electronic properties and conjugated structure. Its planar aromatic ring structure can easily penetrate the cell membrane, so it has certain biological activity, but its anti-breast cancer activity is not high, and its water solubility is poor, which is not conducive to the absorption of drugs in vivo. Copper is an essential element for key cellular functions such as mitochondrial respiration, cholesterol biosynthesis and immune response. The homeostasis of copper in the human body is strictly regulated. The imbalance of copper homeostasis can lead to metabolic abnormalities and toxic effects on cells. Copper death, as a new type of cell death, induces tumor cell death through excessive intracellular copper. The mechanism of copper death is different from all other known regulatory cell death mechanisms, including apoptosis, ferroptosis, pyroptosis and programmed necrosis. The discovery of this mechanism provides new ideas for the design of copper-based anticancer drugs. However, the current cancer treatment methods based on copper death, whether using copper ion carriers or forming nanoparticles, are subject to certain restrictions.
[0040] In view of this, the present invention provides a novel copper complex, which, as a copper death inducer, can enhance the immunogenicity of tumor cells, reshape the immunosuppressive microenvironment, and activate anti-tumor immune response, thus overcoming the defects of existing tumor immunotherapy and greatly improving the clinical tumor immunotherapy effect.
[0041] The novel copper complex provided by the present invention and its effects are described below through specific examples.
[0042] In the following examples, DPQ represents pyrazino[2,3-f][1,10]phenanthroline, Tyr represents tyrosine, Gly represents glycine, Ala represents alanine, and Cys represents cysteine.
[0043] Example 1
[0044] This embodiment provides a copper complex I and a preparation method thereof:
[0045] (1) The chemical formula of the copper complex I is: [Cu(DPQ)(Tyr)(H2O)]PF6·2.5H2O, which belongs to the orthorhombic system, the space group is P 21 21 21, and the unit cell parameters are α=90°,β=90°,γ=90°,Z=4,unit cell volume
[0046] Its spatial structure is Figure 1 As shown, it can be seen that its basic unit consists of a [Cu(DPQ)(Tyr)(H2O)] cation, a PF6 anion and 2.5 free water molecules, in which a Cu atom forms a five-coordinate configuration with two N atoms of a DPQ ligand, an O atom and N atom of tyrosine, and an O atom from a water molecule. According to Addison-Reedijk geometry calculation, the coordination configuration of the Cu ion is a square pyramid (τ = 0.17), whose equatorial plane is composed of two N atoms of DPQ and N and O atoms of tyrosine, and the O atom of the water molecule occupies the axial position.
[0047] (2) The preparation method of the copper complex I is:
[0048] Dissolve 1 mmol of tyrosine and 1 mmol of sodium hydroxide in 20 mL of water, add 1 mmol of copper chloride and 20 mL of ethanol solution of 1 mmol of DPQ under stirring at room temperature, heat under reflux and stir for 3 hours, add 1 mmol of KPF6, continue heating under reflux for 2 hours, cool, filter, and the filtrate evaporates slowly at room temperature. After 4 weeks, blue crystals suitable for X-ray analysis are precipitated, and the yield is about 40% (calculated as copper salt).
[0049] The obtained blue crystals were subjected to X-ray diffraction analysis, and the experimental values of elemental analysis were: C, 40.36; H, 3.70; N, 10.22. Theoretical value (C 23 H 25 CuF6N5O 6.5 P): C, 40.38; H, 3.68; N, 10.23.
[0050] The obtained blue crystals were analyzed by infrared spectroscopy (KBr, ν, cm -1 )(like Figure 2 As shown), the wave numbers from large to small are: 3628, 3346, 3251, 1624, 1516, 1489, 1409, 1388, 1249, 1130, 1085, 856, 731, 651, 559, 439.
[0051] Combined with X-ray diffraction crystal structure and infrared spectrum analysis, it was proved that copper complex Ⅰ was successfully synthesized.
[0052] Example 2
[0053] This embodiment provides a copper complex II and a preparation method thereof:
[0054] (1) The chemical formula of the copper complex I is: [Cu(DPQ)(Gly)(NO3)(H2O)]·1.5H2O, which belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=85.813(3)°,β=88.092(3)°,γ=71.145(3)°,Z=2,unit cell volume
[0055] Its spatial structure is Figure 3 As shown, it can be seen that its basic unit consists of one [Cu(DPQ)(Gly)(NO3)(H2O)] and 1.5 free water molecules. Among them, one Cu atom forms a six-coordinate configuration with two N atoms of a DPQ ligand, one O and N atom of glycine, one O atom of nitrate, and one O atom of a water molecule. According to Addison-Reedijk geometry calculation, the coordination configuration of the Cu ion is a trigonal bipyramid, whose equatorial plane is composed of two N atoms of DPQ and N and O atoms of glycine, and the O atom of the water molecule and the O atom of the nitrate occupy the axial position.
[0056] (2) The preparation method of the copper complex II is:
[0057] Dissolve 1 mmol of glycine and 1 mmol of sodium hydroxide in 20 mL of water, add 1 mmol of copper nitrate and 20 mL of ethanol solution of 1 mmol of DPQ under stirring at room temperature, heat under reflux and stir for 5 hours, continue stirring at room temperature for 1 hour, filter, and allow the filtrate to evaporate slowly at room temperature. After 4 weeks, blue crystals suitable for X-ray analysis are precipitated, with a yield of about 46% (calculated as copper salt).
[0058] The obtained blue crystals were subjected to X-ray diffraction analysis, and the experimental values of elemental analysis were: C, 40.27; H, 3.62; N, 17.60. Theoretical value (C 16 H 17 CuN6O 7.5 ): C, 40.29; H, 3.59; N, 17.62.
[0059] The obtained blue crystals were analyzed by infrared spectroscopy (KBr, ν, cm -1 )(like Figure 4As shown), the wave numbers from large to small are: 3321, 1635, 1593, 1579, 1487, 1406, 1384, 1338, 1311, 1273, 1124, 1080, 1037, 817, 732, 437.
[0060] Combined with X-ray diffraction crystal structure and infrared spectrum analysis, it was proved that the copper complex II was successfully synthesized.
[0061] Example 3
[0062] This embodiment provides a copper complex III and a preparation method thereof:
[0063] (1) The chemical formula of the copper complex III is: [Cu(DPQ)(Ala)(H2O)]·NO3, which belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=80.096(4)°,β=82.903(4)°,γ=85.189(4)°,Z=2,unit cell volume
[0064] Its spatial structure is Figure 5 As shown, it can be seen that its basic unit consists of a [Cu(DPQ)(Ala)(H2O)] cation and a NO3 anion. Among them, a Cu atom forms a five-coordinate configuration with two N atoms of a DPQ ligand, an O and N atom of an alanine ligand, and an O atom of a water molecule. According to Addison-Reedijk geometry calculation, the coordination configuration of the Cu ion is a square pyramid (τ=0.24), whose equatorial plane is composed of two N atoms of DPQ and N and O atoms of alanine, and the O atom of the water molecule occupies the axial position.
[0065] (2) The preparation method of the copper complex III is:
[0066] Dissolve 1 mmol of alanine and 1 mmol of sodium hydroxide in 20 mL of water, add 1 mmol of copper nitrate and 20 mL of ethanol solution of 1 mmol of DPQ under stirring at room temperature, heat under reflux and stir for 5 hours, continue stirring at room temperature for 1 hour, filter, and allow the filtrate to evaporate slowly at room temperature. After 4 weeks, blue crystals suitable for X-ray analysis are precipitated, with a yield of about 41% (calculated as copper salt).
[0067] The obtained blue crystals were subjected to X-ray diffraction analysis, and the experimental values of elemental analysis were: C, 43.98; H, 3.50; N, 18.10. Theoretical value (C 17 H 16 CuN6O6): C, 44.01; H, 3.47; N, 18.11.
[0068] The obtained blue crystals were analyzed by infrared spectroscopy (KBr, ν, cm -1 )(like Figure 6 The wave numbers from largest to smallest are: 3259,1624,1602,1583,1531,1487,1463,1458,1382,1342,1327,1307,1215,1186,1109,1082,1068,835,734,715,669,650,607,559,435.
[0069] Combined with X-ray diffraction crystal structure and infrared spectrum analysis, it was proved that the copper complex III was successfully synthesized.
[0070] Example 4
[0071] This embodiment provides a copper complex IV and a preparation method thereof:
[0072] (1) The chemical formula of the copper complex IV is: [Cu(DPQ)(Cys)] + , which belongs to the orthorhombic system, the space group is P bc a, and the unit cell parameters are α=90°,β=90°,γ=90°,Z=8,unit cell volume
[0073] Its spatial structure is Figure 7 As shown, it can be seen that its basic unit is composed of a [Cu(DPQ)(Cys)] cation. Among them, the two N atoms of the DPQ ligand, the O and N atoms of one cysteine, and the O atom of another cysteine form a five-coordinate configuration. According to Addison-Reedijk geometry calculation, the coordination configuration of the Cu ion is a square pyramid (τ=0.03), whose equatorial plane is composed of the two N atoms of the DPQ ligand and the N and O atoms of cysteine, and the O atom of another cysteine occupies the axial position.
[0074] (2) The preparation method of the copper complex IV is:
[0075] Dissolve 1 mmol of cysteine and 1 mmol of sodium hydroxide in 20 mL of water, add 1 mmol of copper nitrate and 20 mL of ethanol solution of 1 mmol of DPQ under stirring at room temperature, heat under reflux and stir for 5 hours, continue stirring at room temperature for 1 hour, filter, and allow the filtrate to evaporate slowly at room temperature. After 4 weeks, blue crystals suitable for X-ray analysis are precipitated, with a yield of about 41% (calculated as copper salt).
[0076] The obtained blue crystals were subjected to X-ray diffraction analysis, and the experimental values of elemental analysis were: C, 51.37; H, 4.11; N, 15.75. Theoretical value (C 19 H 18CuN5O2S): C, 51.39; H, 4.08; N, 15.77.
[0077] The obtained blue crystals were analyzed by infrared spectroscopy (KBr, ν, cm -1 )(like Figure 8 As shown), the wave numbers from large to small are: 3394, 1635, 1614, 1579, 1531, 1485, 1406, 1384, 1352, 1288, 1213, 1126, 1082, 842, 817, 732, 713, 437.
[0078] Combined with X-ray diffraction crystal structure and infrared spectrum analysis, it was proved that copper complex IV was successfully synthesized.
[0079] The crystal data and structure refinement parameters of copper complexes Ⅰ~Ⅳ are shown in Table 1, and some bond lengths and bond angles of copper complexes Ⅰ~Ⅳ are shown in Table 2.
[0080] Table 1 Crystal data and structure refinement parameters of copper complexes Ⅰ~Ⅳ
[0081]
[0082]
[0083] Table 2 Partial bond length and bond angle data of copper complexes Ⅰ~Ⅳ
[0084]
[0085]
[0086] In order to further verify the performance of copper complexes I to IV, the inventors conducted the following experimental operations:
[0087] Test example
[0088] (I) Evaluation of antitumor activity in vitro
[0089] MTT (thiazolyl blue) method is a method for detecting cell survival and growth. Thiazolyl blue can penetrate the living cell membrane and enter the cell. The succinyl dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to blue-purple formazan crystals that are insoluble in water and precipitate in the cells. The crystals can be dissolved by DMSO. The absorbance value at 570nm can be detected by an enzyme marker, which can indirectly reflect the number of living cells. This method is often used in a large number of anti-tumor drug screening, cytotoxicity tests, and tumor radiosensitivity determinations, and has the advantages of high sensitivity and economy.
[0090] Experimental method: Tumor cells were inoculated into 96-well culture plates, with 2×10 5After incubation for 24 h at 5% CO2 and 37°C, different concentrations of copper complexes I to IV were added to the tumor cells for 72 h. At the same time, control wells (only DPQ) were set up. Each group was set up with 3 replicates. MTT (5 mg mL -1 )10 μL, continue culturing for 4 h, carefully discard the supernatant, add dimethyl sulfoxide (150 μL / well), shake slightly to dissolve the formazan completely, detect the absorbance at 570 nm with an enzyme reader, and then analyze the data.
[0091] Experimental results: The MTT method was used to evaluate the antitumor activity of copper complexes Ⅰ to Ⅳ against triple-negative breast cancer cells CAL-51, MDA-MB-231 and MDA-MB-468, respectively. The experimental results are shown in Table 3.
[0092] At the same time, according to the above method, the antitumor activities of copper complexes [Cu(OH-PIP)(Tyr)(H2O)]PF6 (copper complex 1), [Cu(m-OH-PIP)(Gly)]NO3·2.25H2O (copper complex 2), [Cu(Cl-PIP)(Gly)Br] (copper complex 3), [Cu(F-PIP)(Tyr)Cl] (copper complex 4) and [Cu(F-PIP)(Phe)Br] (copper complex 5) on triple-negative breast cancer cells MDA-MB-468 were detected, and the experimental results are shown in Table 3.
[0093] Table 3 Evaluation of in vitro antitumor activity of copper complexes Ⅰ-Ⅳ, ligand DPQ and copper complexes 1-5
[0094]
[0095] As can be seen from Table 3, after 72 hours of treatment with different concentrations of copper complexes Ⅰ to Ⅳ on the selected tumor cell lines (CAL-51, MDA-MB-231 and MDA-MB-468), the growth and proliferation of the selected tumor cell lines were significantly inhibited. 50 The values ranged from 0.13 to 0.42 μM, while the IC 50 The values were all greater than 100 μM, indicating that copper ions and ligands played a synergistic anti-tumor effect. The IC values of copper complexes I to IV on normal breast epithelial cells MCF 10A 50 The values are all greater than 100 μM, which means that copper complexes I to IV have less cytotoxicity and can be used as potential drugs for treating tumors, especially as drugs against triple-negative breast cancer.
[0096] (II) Cell scratch assay
[0097] When the cells grow to the point of being fused into a monolayer, a blank area called a "scratch" is artificially created on the fused monolayer of cells. The cells at the edge of the scratch will gradually move into the blank area to heal the "scratch", simulating the process of cell migration in vivo to a certain extent. It is a simple method for studying cell migration in vitro experiments.
[0098] An important reason for the poor prognosis of triple-negative breast cancer is the high metastasis rate. In order to study whether copper complexes Ⅰ to Ⅳ can inhibit the migration of triple-negative breast cancer, the cell scratch assay was used to evaluate the anti-migratory potential of copper complexes Ⅰ and Ⅲ on triple-negative breast cancer MDA-MB-468 cells.
[0099] Experimental method: MDA-MB-468 cells in the logarithmic growth phase were digested with trypsin and inoculated into 6-well plates. Approximately 10 5 After culturing for 24 hours, use a 10 μL pipette tip to draw a straight line in the center of the 6-well plate and rinse the fallen cells with PBS. 50 The values were used as references to set up a control group, a positive drug group (cisplatin group) and a sample group (copper complex). The scratch widths at 0h and 24h were observed under a microscope (e.g. Fig. 9 (a)), and the cell migration rate was calculated (as Fig. 9 (b)) (cell migration rate = (0 h scratch area - 24 h scratch area) / 0 h scratch area).
[0100] Experimental results: Fig. 9 (a) It can be seen that compared with the control group, the scratch healing speed of cells in the groups of copper complex I and copper complex III slowed down, while the scratch width of cells in the control group decreased; Fig. 9 (b) It can be seen that the cell migration rate of the control group cells is 38.5%, the cell migration rate of the positive drug group (cisplatin group) is 11.5%, the cell migration rates of the copper complex I low concentration group (0.1μM) and high concentration group (0.2μM) are 23.1% and 7.7%, respectively, and the cell migration rates of the copper complex III low concentration group (0.15μM) and high concentration group (0.30μM) are 19.2% and 7.7%, respectively, indicating that copper complex I and copper complex III can inhibit the migration of triple-negative breast cancer cells; when the concentration of copper complex I or copper complex III is 1 times the IC 50 When the concentration of cisplatin was 0.2 μM and 0.3 μM respectively, the inhibitory effect on the migration of triple-negative breast cancer cells MDA-MB-468 was better than that of the positive drug group (cisplatin group).
[0101] (III) Tumor stem cell mammosphere formation experiment
[0102] The number of tumor stem cells in ordinary cancer cells is relatively small, and it is difficult to sort and culture them. The serum-free medium suspension culture method has successfully achieved the enrichment and culture of stem cells. The microspheres screened by this method are enriched with a large number of tumor stem cells, which simplifies the sorting steps, saves costs, and provides a better cell model for the study of cancer stem cells. Under serum-free culture conditions, tumor stem cells are able to survive because they have stronger self-renewal and differentiation potential than non-tumor stem cells, and tolerate serum-free culture conditions. They can also proliferate when certain growth factors (such as bFGF, EGF, insulin and B27) are added, while non-tumor stem cells have been completely differentiated and cannot grow normally in serum-free culture medium.
[0103] Breast cancer stem cells are a subpopulation of tumor cells that express stem cell-related markers and have a high tumorigenesis ability in vivo. In order to explore the effect of copper complexes on tumor stem cells, the present invention uses a tumor stem cell microsphere formation experiment to study whether copper complexes affect the formation of MDA-MB-468 tumor microspheres.
[0104] Experimental method: The serum-free medium sorting method was used to culture tumor stem cells. MDA-MB-468 cells in the logarithmic growth phase were digested with trypsin, and the cell suspension was centrifuged at 1000 rpm for 5 min. -1 EGF, 20 ng mL -1 bFGF and B27 (1:50) were added to the DMEM / F12 serum-free medium in a centrifuge tube, and the cells were resuspended to form a single cell suspension. 4 The cells were seeded in a non-adhesive 6-well plate at a density of 100 cells / well. A control group, a cisplatin group, a copper complex I group, and a copper complex III group were set up and cultured in a 5% CO2, 37°C cell culture incubator. The cell status was observed on the 1st, 7th, and 14th day, and photos were taken under a microscope (such as Fig.10 shown).
[0105] Experimental results: Fig.10 It can be seen that the tumor microspheres in the control group are dense and round, showing strong spherical stem biological characteristics, while the microspheres in the drug-treated group are loose. After adding cisplatin, copper complex I and copper complex III, the growth of the microspheres can be inhibited and their morphology can be destroyed. This shows that copper complex I and copper complex III have a strong killing effect on MDA-MB-468 tumor stem cell microspheres, which affects the self-renewal and proliferation ability of stem cells in the microspheres.
[0106] (IV) Flow cytometry detection of tumor cell stemness markers CD44+CD24-
[0107] Cancer stem cells (CSCs) are a minority of cell subpopulations with stem cell characteristics existing in tumor tissues. They have self-renewal ability and multidirectional differentiation potential, and are considered to be the root of tumor resistance, recurrence and metastasis, and are associated with highly invasive triple-negative breast cancer. CD44+CD24- is a stemness marker of MDA-MB-468 cells. In order to explore the effects of copper complexes I and III on cancer stem cells, flow cytometry was used to detect the CD44+CD24- phenotype in MDA-MB-468 cells treated with copper complexes.
[0108] Experimental method: MDA-MB-468 cells in the logarithmic phase were digested with trypsin, the cell suspension was centrifuged at 1000 rpm for 5 min, and 5×10 4 Cells were inoculated in a 6-well plate at a density of 100 μL / well, and copper complex I (0.1 μM, 0.2 μM) and copper complex III (0.15 μM, 0.30 μM) were added for 48 h respectively; the cells were digested and centrifuged, and the cells were washed twice with PBS, the supernatant was discarded, and the cells were resuspended with 100 μL of PBS, and 10 μL of CD44 and / or CD24 were added: the compound treatment group was double-stained; the blank cells were divided into 4 groups, double negative, CD44 single staining, CD24 single staining, and double positive. Incubate at 4℃ in the dark for 20 min, centrifuge and discard the supernatant, and finally add 300 μL of PBS to the cells, resuspend and test on the machine. The results are as follows Fig.11 shown.
[0109] Experimental results: After treatment with copper complex I at concentrations of 0.1μM and 0.2μM, the number of CD44+CD24- cells in the control group decreased from 98.1% to 94% and 79.1% respectively; after treatment with copper complex III at concentrations of 0.15μM and 0.30μM, the number of CD44+CD24- cells in the control group decreased from 95.5% to 80.2% and 75.2% respectively. In the treatment of breast cancer, eliminating breast cancer stem cells is the key to completely cure the disease. The results of this experiment show that copper complex I and copper complex III have the ability to inhibit tumor stemness.
[0110] (V) Western blotting assay to detect tumor cell stemness
[0111] Breast cancer stem cells are the main source of breast cancer resistance, metastasis and recurrence. In-depth research on the mechanism of CSCs resistance, metastasis and recurrence during treatment is the key to developing CSCs targeted treatment strategies. Nanog gene is a transcription factor of tumor stem cells, which plays a key role in maintaining the multipotent differentiation of stem cells, regulating cell proliferation and asymmetric division. Recent studies have shown that upregulation of Nanog expression is closely related to the late stage of malignant tumors and poor prognosis, and plays a key role in the occurrence of various human tumors including breast cancer. Nanog induces the stemness, self-renewal, metastasis, invasiveness and chemotherapy resistance of cancer cells through different signaling pathways.
[0112] Epithelial-mesenchymal transition (EMT) is an aggressive feature of TNBC subtypes that can lead to cell invasion and distant metastasis. Normally, epithelial cells are connected together in an extracellular matrix environment to maintain tissue stability. However, in tumor cells, EMT is a multistep process that involves the loss of polarity of normal epithelial cells and detachment from the basement membrane. EMT conversion can enhance the mobility of tumor cells and initiate the metastatic process. A characteristic change of EMT is the loss of expression of epithelial cell markers such as E-cadherin and the increase in expression of mesenchymal cell marker proteins such as Vimentin. In breast cancer, the occurrence of EMT promotes the acquisition of cancer stem cell-like properties, the formation of tumor spheres, and the presentation of BCSCs-specific phenotypic markers CD44+ / CD24-.
[0113] Experimental results: Western blotting was used to detect the expression changes of breast cancer cell stemness-related proteins such as Nanog, SOX2 and EMT markers E-cadherin (denoted as E-cad) and Vimentin (denoted as VIM) to determine the effect of copper complexes on the stemness of triple-negative breast cancer MDA-MB-468 cells, thereby providing a reference for the development of related drugs. The experimental results are as follows Fig.12 shown.
[0114] Depend on Fig.12 It can be seen that compared with the control group, after adding copper complex I (0.1μM, 0.2μM) and copper complex III (0.15μM, 0.30μM), the expression of epithelial cell marker E-cadherin protein was significantly upregulated, while the expression of mesenchymal cell marker Vimentin protein was downregulated, indicating that copper complex I and copper complex III can inhibit the occurrence of EMT in MDA-MB-468 cells, thereby inhibiting the stemness of tumor cells. In addition, after treating MDA-MB-468 cells with different concentrations of copper complex I and copper complex III, the expression of tumor stem cell transcription factors Nanog and SOX2 proteins was downregulated with the increase of concentration, which also shows that copper complex I and copper complex III can inhibit the stemness of tumor cells.
[0115] (VI) Copper complexes induce copper death of tumor cells
[0116] After the designed and synthesized copper complex selectively enters breast cancer cells, copper ions bind to dihydrolipoamide S-acetyltransferase (DLAT), inducing DLAT oligomerization, leading to protein toxic stress, thereby triggering copper death. At the same time, iron-sulfur (Fe-S) cluster protein lipoyl synthase (LISA) is downregulated due to Cu+ interference, leading to the loss of Fe-S cluster protein.
[0117] Experimental results: Western blotting was used to detect the expression changes of copper-related death proteins such as FDX1, LIAS, and DLAT in tumor cells to determine the effect of copper complexes on copper death in tumor cells, thereby providing a reference for the development of copper-related death drugs. The experimental results are as follows Fig.13 shown.
[0118] Depend on Fig.13 It can be seen that compared with the control group, the expression of DLAT protein decreased after the addition of copper complex I (0.1μM, 0.2μM) and copper complex III (0.15μM, 0.30μM), which may be due to the binding of copper ions to DLAT, resulting in DLAT oligomerization, and the expression of LIAS and FDX1 was also significantly reduced, indicating that copper complexes induce strong copper death in tumor cells.
[0119] (VII) Anti-tumor effects of copper complexes in vivo
[0120] According to the above experimental results, the breast cancer cell line MDA-MB-468 nude mouse transplant tumor model was selected to test the in vivo anti-tumor activity of copper complex I and copper complex III. The dosage was 30 mg / kg, and the intraperitoneal injection was given twice a day for 14 consecutive days. The results showed (Table 4) that copper complex I and copper complex III both showed excellent in vivo inhibitory activity, with in vivo tumor inhibition rates of 81.1% and 85.3%, respectively, which were better than the positive drug group (cisplatin) (70.5%) at the same dose. In addition, no significant changes in the weight of mice were found during the administration period, indicating that copper complex I and copper complex III have low in vivo toxicity and are worth further study.
[0121] Table 4 The efficacy of copper complex I, copper complex III and cisplatin on MDA-MB-468 nude mouse xenograft tumors
[0122]
[0123] In summary, the present invention has carried out a series of the above-mentioned pharmacological experiments represented by copper complex I and copper complex III: tumor stem cell microsphere formation experiment, scratch experiment, flow cytometry experiment and protein immunoblotting experiment jointly confirmed that the copper complex provided by the present invention can inhibit the formation of tumor stem cell microspheres, cell migration and tumor stemness. In addition, protein immunoblotting experiments confirmed that the copper complex provided by the present invention can promote copper cell death in tumor cells, and in vivo experiments confirmed that the copper complex provided by the present invention has significant in vivo efficacy. It shows that copper complexes can be used as potential anti-tumor stemness drugs for cancer treatment, especially for the preparation of drugs to treat triple-negative breast cancer.
[0124] What is described above is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A copper complex, characterized in that The chemical formula of the copper complex is: [Cu(DPQ)(Tyr)(H2O)]PF6·2.5H2O Formula I, [Cu(DPQ)(Gly)(NO3)(H2O)]·1.5H2O Formula II, [Cu(DPQ)(Ala)(H2O)]·NO3 Formula III or [Cu(DPQ)(Cys)] + Formula IV; Among them, DPQ is pyrazino[2,3-f][1,10]phenanthroline, Tyr is tyrosine, Gly is glycine, Ala is alanine, Cys is cysteine, PF6 is hexafluorophosphate, and NO3 is nitrate.
2. The copper complex according to claim 1, characterized in that The copper complex I crystal belongs to the orthorhombic system, the space group is P 21 21 21, and the unit cell parameters are α=90°,β=90°,γ=90°,Z=4,unit cell volume The copper complex II crystal belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=85.813(3)°,β=88.092(3)°,γ=71.145(3)°,Z=2,unit cell volume The copper complex III crystal belongs to the triclinic system, the space group is P-1, and the unit cell parameters are α=80.096(4)°,β=82.903(4)°,γ=85.189(4)°,Z=2,unit cell volume The copper complex IV crystal belongs to the orthorhombic system, the space group is Pb ca, and the unit cell parameters are α=90°,β=90°,γ=90°,Z=8,unit cell volume 3. A method for preparing the copper complex according to claim 1 or 2, characterized in that the steps include: Dissolve equimolar amounts of amino acid and alkali in water, add an alcohol solution containing equimolar amounts of metal copper salt and ligand under stirring at room temperature, heat under reflux and stir for 3 to 5 hours, continue heating under reflux for 2 hours or stir at room temperature for 1 hour, filter, and evaporate the filtrate at room temperature. After 3 to 5 weeks, blue crystals of the copper complex are obtained.
4. The method for preparing the copper complex according to claim 3, characterized in that: After heating under reflux and stirring for 3 to 5 hours, an equimolar amount of hexafluorophosphate was added, and then heating under reflux was continued for 2 hours.
5. The method for preparing the copper complex according to claim 4, characterized in that: The hexafluorophosphate includes at least one of potassium hexafluorophosphate, lithium hexafluorophosphate, sodium hexafluorophosphate and ammonium hexafluorophosphate.
6. The method for preparing the copper complex according to claim 3, characterized in that: The metal copper salt includes at least one of copper chloride, copper bromide, copper carbonate, copper nitrate and copper perchlorate.
7. A pharmaceutical composition of a copper complex, comprising the copper complex according to claim 1 or 2 and an excipient.
8. Use of the copper complex according to claim 1 or 2 in the preparation of a copper death inducing agent or in the preparation of an anti-tumor stemness drug.
9. Use of the copper complex according to claim 1 or 2 in the preparation of an anti-triple-negative breast cancer drug.
10. The use according to claim 9, characterized in that The anti-triple negative breast cancer cells are anti-triple negative breast cancer cells CAL-51, MDA-MB-231 and / or MDA-MB-468.
Citation Information
Patent Citations
Amino acid polypyridyl copper complex and preparation method and application thereof
CN106883251A
